Purines in parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection

The Adenosinergic System: A Non-Dopaminergic Target in Parkinson's Disease

Volumn , Issue , 2015, Pages 101-126

  Bakshi, Rachit ^a   Logan, Robert ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adenosine A2A receptor; Caffeine; Clinical trials; Neurodegenerative disease; Neuroprotection; Parkinson's disease; Purines; Risk factor; Urate

Indexed keywords

EID: 84955685742     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-20273-0_6     Document Type: Chapter

References (224)

1. Abraham A, Drory VE (2014) Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 261:1133-1138
2. Ahlskog JE, Uitti RJ, Low PA et al (1995) No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 10:566-573
3. Alfinito PD, Wang SP, Manzino L et al (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 23:10982-10987
4. Al-Khateeb E, Althaher A, Al-Khateeb M et al (2015) Relation between uric acid and Alzheimer's disease in elderly Jordanians. J Alzheimers Dis 44:859-865
5. Alonso A, Rodriguez LA, Logroscino G et al (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696-1700
6. Amaro S, Canovas D, Castellanos M et al (2010) The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms. Int J Stroke 5:325-328
7. Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78:6858-6862
8. Andreadou E, Nikolaou C, Gournaras F et al (2009) Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111:724-728
9. Annanmaki T, Muuronen A, Murros K (2007) Low plasma uric acid level in Parkinson's disease. Mov Disord 22:1133-1137
10. Arendash GW, Schleif W, Rezai-Zadeh K et al (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142:941-952
11. Arendash GW, Mori T, Cao C et al (2009) Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis 17:661-680
12. Armentero MT, Pinna A, Ferré S et al (2011) Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther 132:280-299
13. Ascherio A, Zhang SM, Hernan MA et al (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63
14. Ascherio A, LeWitt PA, Xu K et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66:1460-1468
15. Atassi N, Berry J, Shui A et al (2014) The PRO-ACT database: design, initial analyses, and predictive features. Neurology 83:1719-1725
16. Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington's disease progression. Mov Disord 25:224-228
17. Banks WA, Erickson MA (2009) The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 37:26-32
18. Beghi E, Pupillo E, Messina P et al (2011) Coffee and amyotrophic lateral sclerosis: a possible preventive role. Am J Epidemiol 174:1002-1008
19. Belcastro V, Tozzi A, Tantucci M et al (2009) A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Exp Neurol 217:231-234
20. Benedetti MD, Bower JH, Maraganore DM et al (2000) Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 55:1350-1358
21. Benzie I, Strain J (1996) Uric acid: friend or foe? Redox Rep 2:231-234
22. Bibbiani F, Oh JD, Petzer JP et al (2003) A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184:285-294
23. Blum D, Galas MC, Pintor A et al (2003) A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J Neurosci 23:5361-5369
24. Bogdanov M, Matson WR, Wang L et al (2008) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131:389-396
25. Bos MJ, Koudstaal PJ, Hofman A et al (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37:1503-1507
26. Brambilla R, Cottini L, Fumagalli M et al (2003) Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43:190-194
27. Brambilla L, Martorana F, Rossi D (2012) Astrocyte signaling and neurodegeneration: new insights into CNS disorders. Prion 7:28-36
28. Brodie C, Blumberg PM, Jacobson KA (1998) Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 429:139-142
29. Brothers HM, Marchalant Y, Wenk GL (2010) Caffeine attenuates lipopolysaccharide-induced neuroinflammation. Neurosci Lett 480:97-100
30. Burton NC, Kensler TW, Guilarte TR (2006) In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 27:1094-1100
31. Can M, Varlibas F, Guven B et al (2013) Ischemia modified albumin and plasma oxidative stress markers in Alzheimer's disease. Eur Neurol 69:377-380
32. Cankurtaran M, Yesil Y, Kuyumcu ME et al (2012) Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer's disease. J Alzheimers Dis 33:1051-1058
33. Cao C, Cirrito JR, Lin X et al (2009) Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 17:681-697
34. Cao B, Guo X, Chen K et al (2013) Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population. J Neurol 260:2511-2515
35. Carta AR, Kachroo A, Schintu N et al (2009) Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 111:1478-1489
36. Caulfield MJ, Munroe PB, O'Neill D et al (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 5:e197
37. Chamorro A, Obach V, Cervera A et al (2002) Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 33:1048-1052
38. Chamorro A, Amaro S, Castellanos M et al (2014) Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol 13:453-460
39. Checkoway H, Powers K, Smith-Weller T et al (2002) Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155:732-738
40. Chen Y, Vartiainen NE, Ying W et al (2001a) Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J Neurochem 77:1601-1610
41. Chen JF, Xu K, Petzer JP et al (2001b) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143
42. Chen PS, Peng GS, Li G et al (2006) Valproate protects dopaminergic neurons in midbrain neuron/ glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11:1116-1125
43. Chen H, Mosley TH, Alonso A et al (2009a) Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 169:1064-1069
44. Chen PC, Vargas MR, Pani AK et al (2009b) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 106:2933-2938
45. Chen X, Ghribi O, Geiger JD (2010) Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis 20:S127-S141
46. Chen X, Burdett TC, Desjardins CA et al (2013) Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 110:300-305
47. Chen X, Guo X, Huang R et al (2014) Serum uric acid levels in patients with Alzheimer's disease:a meta-analysis. PLoS One 9:e94084
48. Chou SY, Lee YC, Chen HM et al (2005) CGS 21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 93:310-320
49. Christen P, Peacock WC, Christen AE et al (1970) Urate oxidase in primate phylogenesis. Eur J Biochem 12:3-5
50. Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson's disease:effect on dopamine oxidation. Brain Res Bull 33:419-425
51. Cipriani S, Desjardins CA, Burdett TC et al (2012a) Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS One 7:e37331
52. Cipriani S, Desjardins CA, Burdett TC et al (2012b) Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J Neurochem 123:172-181
53. Cunha RA (2005) Neuroprotection by adenosine in the brain: from A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal 1:111-134
54. Daly JW, Butts-Lamb P, Padgett W (1983) Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol 3:69-80
55. Davis JW, Grandinetti A, Waslien CI et al (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 144:480-484
56. de Lau LM, Koudstaal PJ, Hofman A et al (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797-800
57. De Luca MA, Cauli O, Morelli M et al (2014) Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? J Neurochem 131:284-289
58. de Mendonça A, Sebastiao AM, Ribeiro JA (2000) Adenosine: does it have a neuroprotective role after all? Brain Res Rev 33:258-274
59. De Vera M, Rahman MM, Rankin J et al (2008) Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum 59:1549-1554
60. Dehghan A, Kottgen A, Yang Q et al (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372:1953-1961
61. Dheen ST, Kaur C, Ling EA (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14:1189-1197
62. D'Hooghe MB, Haentjens P, Nagels G et al (2012) Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol 19:616-624
63. Du Y, Chen CP, Tseng CY et al (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55:463-472
64. Duan W, Ladenheim B, Cutler RG et al (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80:101-110
65. Ellrichmann G, Petrasch-Parwez E, Lee DH et al (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 6:e16172
66. Erickson MA, Dohi K, Banks WA (2012) Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation 19:121-130
67. Eskelinen MH, Kivipelto M (2010) Caffeine as a protective factor in dementia and Alzheimer's disease. J Alzheimers Dis 20:S167-S174
68. Eskelinen MH, Ngandu T, Tuomilehto J et al (2009) Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 16:85-91
69. Euser SM, Hofman A, Westendorp RG et al (2009) Serum uric acid and cognitive function and dementia. Brain 132:377-382
70. Facheris MF, Hicks AA, Minelli C et al (2011) Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 43:246-250
71. Fall PA, Fredrikson M, Axelson O et al (1999) Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 14:28-37
72. Fiebich BL, Biber K, Lieb K et al (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18:152-160
73. Fiebich BL, Butcher RD, Gebicke-Haerter PJ (1998) Protein kinase C-mediated regulation of inducible nitric oxide synthase expression in cultured microglial cells. J Neuroimmunol 92:170-178
74. Filippo MD, Chiasserini D, Tozzi A et al (2010) Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis 20:S369-S379
75. Fink JS, Kalda A, Ryu H et al (2004) Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J Neurochem 88:538-544
76. Fredholm BB, Battig K, Holmen J et al (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133
77. Fujishita K, Ozawa T, Shibata K et al (2009) Grape seed extract acting on astrocytes reveals neuronal protection against oxidative stress via interleukin-6-mediated mechanisms. Cell Mol Neurobiol 29:1121-1129
78. Gao Y, Phillis JW (1994) CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci 55:PL61-PL65
79. Gao X, Chen H, Choi HK et al (2008) Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 167:831-838
80. Gerhard A, Pavese N, Hotton G et al (2006) In vivo imaging of microglial activation with [11C] (R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404-412
81. Gong L, Zhang QL, Zhang N et al (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3beta signaling pathway. J Neurochem 123:876-885
82. Gonsette RE, Sindic C, D'Hooghe MB et al (2010) Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. Mult Scler 16:455-462
83. Gonzalez-Aramburu I, Sanchez-Juan P, Jesus S et al (2013) Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. Mov Disord 28:1737-1740
84. Gonzalez-Fernandez E, Sanchez-Gomez MV, Perez-Samartin A et al (2014) A3 Adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve. Glia 62(2):199-216
85. Guerreiro S, Ponceau A, Toulorge D et al (2009) Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 109:1118-1128
86. Haberman F, Tang SC, Arumugam TV et al (2007) Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neuromolecular Med 9:315-323
87. Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 51:35-42
88. Hediger MA, Johnson RJ, Miyazaki H et al (2005) Molecular physiology of urate transport. Physiology 20:125-133
89. Hellenbrand W, Boeing H, Robra BP et al (1996) Diet and Parkinson's disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47:644-650
90. Hindley S, Herman MA, Rathbone MP (1994) Stimulation of reactive astrogliosis in vivo by extracellular adenosine diphosphate or an adenosine A2 receptor agonist. J Neurosci Res 38:399-406
91. Hooper DC, Spitsin S, Kean RB et al (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 95:675-680
92. Hooper DC, Scott GS, Zborek A et al (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14:691-698
93. Hozawa A, Folsom AR, Ibrahim H et al (2006) Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 187:401-407
94. Hu G, Bidel S, Jousilahti P et al (2007) Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 22:2242-2248
95. Huang QY, Wei C, Yu L et al (2006) Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. J Neurosci 26:11371-11378
96. Huang NK, Lin JH, Lin JT et al (2011) A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One 6:e20934
97. Iadecola C, Zhang F, Xu S et al (1995) Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 15:378-384
98. Ikeda K, Kurokawa M, Aoyama S et al (2002) Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80:262-270
99. Ikeda K, Hirayama T, Takazawa T et al (2012) Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 51:1501-1508
100. Imamura K, Takeshima T, Nakaso K et al (2008) Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neurosci Lett 440:97-102
101. Innamorato NG, Jazwa A, Rojo AI et al (2010) Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 5:e11838
102. Irizarry MC, Raman R, Schwarzschild MA et al (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6:23-28
103. Jakel RJ, Townsend JA, Kraft AD et al (2007) Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 1144:192-201
104. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53:S26-S36
105. Jesus S, Perez I, Caceres-Redondo MT et al (2012) Low serum uric acid concentration in Parkinson's disease in southern Spain. Eur J Neurol 20:208-210
106. Jinnah HA, Ceballos-Picot I, Torres RJ et al (2010) Attenuated variants of Lesch-Nyhan disease. Brain 133:671-689
107. Joghataie MT, Roghani M, Negahdar F et al (2004) Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 10:465-468
108. Johansen KK, Wang L, Aasly JO et al (2009) Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 4:e7551
109. Jones DC, Gunasekar PG, Borowitz JL et al (2000) Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J Neurochem 74:2296-2304
110. Joshi G, Johnson JA (2012) The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 7:218-229
111. Kachroo A, Irizarry MC, Schwarzschild MA (2010) Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 223:657-661
112. Kataoka H, Kiriyama T, Kobayashi Y et al (2013) Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged ≥ 70 years. Am J Neurodegener Dis 2:140-144
113. Keebaugh AC, Thomas JW (2010) The evolutionary fate of the genes encoding the purine catabolic enzymes in hominoids, birds, and reptiles. Mol Biol Evol 27:1359-1369
114. Keizman D, Ish-Shalom M, Berliner S et al (2009) Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 285:95-99
115. Kim TS, Pae CU, Yoon SJ et al (2006) Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21:344-348
116. Kolz M, Johnson T, Sanna S et al (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5:e1000504
117. Kroncke KD, Fehsel K, Kolb-Bachofen V (1998) Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 113:147-156
118. Kutzing MK, Firestein BL (2008) Altered uric acid levels and disease states. J Pharmacol Exp Ther 324:1-7
119. Ladecola C, Zhang F, Xu S et al (1995) Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 15:378-384
120. Larumbe Ilundain R, Ferrer Valls JV, Vines Rueda JJ et al (2001) Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease. Rev Esp Salud Publica 75:43-53
121. Laurent C, Eddarkaoui S, Derisbourg M et al (2014) Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging 35:2079-2090
122. Lee CF, Chern Y (2014) Adenosine receptors and Huntington's disease. Int Rev Neurobiol 119:195-232
123. Lee JE, Song SK, Sohn YH et al (2011) Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 26:1533-1536
124. Lekieffre D, Callebert J, Plotkine M et al (1991) Enhancement of endogenous excitatory amino acids by theophylline does not modify the behavioral and histological consequences of forebrain ischemia. Brain Res 565:353-357
125. Li XX, Nomura T, Aihara H et al (2001) Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci 68:1343-1350
126. Li S, Sanna S, Maschio A et al (2007) The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 3:e194
127. Li XZ, Bai LM, Yang YP et al (2009) Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced inflammation. Neurosci Res 65:252-258
128. Licinio J, Prolo P, McCann SM et al (1999) Brain iNOS: current understanding and clinical implications. Mol Med Today 5:225-232
129. Lindsay J, Laurin D, Verreault R et al (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156:445-453
130. Lipkowitz MS (2012) Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep 14:179-188
131. Machado-Filho JA, Correia AO, Montenegro AB et al (2014) Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. Behav Brain Res 264:116-125
132. Maesaka JK, Wolf-Klein G, Piccione JM et al (1993) Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J Am Geriatr Soc 41:501-506
133. Markowitz CE, Spitsin S, Zimmerman V et al (2009) The treatment of multiple sclerosis with inosine. J Altern Complement Med 15:619-625
134. Massa J, O'Reilly EJ, Munger KL et al (2012) Caffeine and alcohol intakes have no association with risk of multiple sclerosis. Mult Scler 19:53-58
135. Matos M, Augusto E, Agostinho P et al (2013) Antagonistic interaction between adenosine A2A receptors and Na+/K+-ATPase-α2 controlling glutamate uptake in astrocytes. J Neurosci 33:18492-18502
136. McCall AL, Millington WR, Wurtman RJ (1982) Blood-brain barrier transport of caffeine: doserelated restriction of adenine transport. Life Sci 31:2709-2715
137. McDermott MP, Hall WJ, Oakes D et al (2002) Design and analysis of two-period studies of potentially disease-modifying treatments. Control Clin Trials 23:635-649
138. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23:474-483
139. Melani A, Cipriani S, Vannucchi MG et al (2009) Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain 132:1480-1495
140. Merck Sharp & Dohme Corp. (2015) A placebo- and active-controlled study of preladenant in early Parkinson's disease. http://clinicaltrials.gov/show/NCT01155479
141. Mievis S, Blum D, Ledent C (2011) A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol Dis 41:570-576
142. Minghetti L, Greco A, Potenza RL et al (2007) Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol 66:363-371
143. Moccia M, Picillo M, Erro R et al (2014) Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. Eur J Neurol 22:93-98
144. Morelli M, Carta AR, Jenner P (2009) Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol 193:589-615
145. Morelli M, Carta AR, Kachroo A et al (2010) Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res 183:183-208
146. Morozova N, Weisskopf MG, McCullough ML et al (2008) Diet and amyotrophic lateral sclerosis. Epidemiology 19:324-337
147. Munoz Garcia D, Midaglia L, Martinez Vilela J et al (2015) Associated Inosine to interferon: results of a clinical trial in multiple sclerosis. Acta Neurol Scand. 131:405-410
148. Neymotin A, Calingasan NY, Wille E et al (2011) Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med 51:88-96
149. Niranjan R (2013) The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol Neurobiol 49:28-38
150. Nishizaki T (2004) ATP- and adenosine-mediated signaling in the central nervous system: adenosine stimulates glutamate release from astrocytes via A2a adenosine receptors. J Pharmacol Sci 94:100-102
151. Oda M, Satta Y, Takenaka O et al (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640-653
152. O'Reilly EJ, Gao X, Weisskopf MG et al (2010) Plasma urate and Parkinson's disease in women. Am J Epidemiol 172:666-670
153. Orowan E (1955) The origin of man. Nature 175:683-684
154. Ostwald P, Park SS, Toledano AY et al (1997) Adenosine receptor blockade and nitric oxide synthase inhibition in the retina: impact upon post-ischemic hyperemia and the electroretinogram. Vision Res 37:3453-3461
155. Paganoni S (2014) A Pilot Study of Inosine in ALS. http://clinicaltrials.gov/NCT02288091. Accessed July 2015
156. Paganoni S, Zhang M, Quiroz Zarate A et al (2012) Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259:1923-1928
157. Parkinson's-Study-Group, Schwarzschild MA, Ascherio A et al (2014) Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 71:141-150
158. Pierri M, Vaudano E, Sager T et al (2005) KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48:517-524
159. Pinna A (2014) Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28:455-474
160. Pinna A, Tronci E, Schintu N et al (2010) A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58:613-623
161. Polidori MC, Mattioli P, Aldred S et al (2004) Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 18:265-270
162. Popoli P, Pintor A, Domenici MR et al (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22:1967-1975
163. Postuma R (2015) Caffeine as a therapy for Parkinson's disease. http://clinicaltrials.gov/show/ NCT01738178. Accessed July 2015
164. Postuma RB, Lang AE, Munhoz RP et al (2012) Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 79:651-658
165. Potenza RL, Armida M, Ferrante A et al (2013) Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 91:585-592
166. Prasanthi JR, Dasari B, Marwarha G et al (2010) Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med 49:1212-1220
167. Proctor P (1970) Similar functions of uric acid and ascorbate in man? Nature 228:868
168. PSG (1989a) Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 321:1364-1371
169. PSG (1989b) DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 46:1052-1060
170. PSG (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183
171. PSG (2007) Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69:1480-1490
172. Pugliese AM, Traini C, Cipriani S et al (2009) The adenosine A2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices. Br J Pharmacol 157:818-830
173. Ragonese P, Salemi G, Morgante L et al (2003) A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. Neuroepidemiology 22:297-304
174. Rathinam ML, Watts LT, Narasimhan M et al (2012) Astrocyte mediated protection of fetal cerebral cortical neurons from rotenone and paraquat. Environ Toxicol Pharmacol 33:353-360
175. Rinaldi P, Polidori MC, Metastasio A et al (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24:915-919
176. Romanos E, Planas AM, Amaro S et al (2007) Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 27:14-20
177. Ross GW, Abbott RD, Petrovitch H et al (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-2679
178. Rudolphi KA, Schubert P, Parkinson FE et al (1992) Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 4:346-369
179. Saura J, Angulo E, Ejarque A et al (2005) Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95:919-929
180. Scatena A, Fornai F, Trincavelli ML et al (2011) 3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4] triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)- mediated neuroprotective effects. ACS Chem Neurosci 2:526-535
181. Schwarzschild MA, Xu K, Oztas E et al (2003) Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 61:S55-S61
182. Schwarzschild MA, Agnati L, Fuxe K et al (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29:647-654
183. Schwarzschild MA, Schwid SR, Marek K et al (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65:716-723
184. Schwarzschild MA, Macklin EA, Ascherio A (2014) Urate and neuroprotection trials. Lancet Neurol 13:758
185. Scott GS, Spitsin SV, Kean RB et al (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 99:16303-16308
186. Scott GS, Cuzzocrea S, Genovese T et al (2005) Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 102:3483-3488
187. Seida M, Wagner HG, Vass K et al (1988) Effect of aminophylline on postischemic edema and brain damage in cats. Stroke 19:1275-1282
188. Serra PA, Sciola L, Delogu MR et al (2002) The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J Biol Chem 277:34451-34461
189. Simon DK, Swearingen CJ, Hauser RA et al (2008) Caffeine and progression of Parkinson disease. Clin Neuropharmacol 31:189-196
190. Simon KC, Eberly S, Gao X et al (2014) Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol 76:862-868
191. Simonin C, Duru C, Salleron J et al (2013) Association between caffeine intake and age at onset in Huntington's disease. Neurobiol Dis 58:179-182
192. So A, Thorens B (2010) Uric acid transport and disease. J Clin Invest 120:1791-1799
193. Sonsalla PK, Wong LY, Harris SL et al (2012) Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease. Exp Neurol 234:482-487
194. Spasojevic I, Stevic Z, Nikolic-Kokic A et al (2010) Different roles of radical scavengers-ascorbate and urate in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 15:81-86
195. Spitsin S, Hooper DC, Leist T et al (2001) Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7:313-319
196. Stevens B, Porta S, Haak LL et al (2002) Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 36:855-868
197. Stocchi F, Rascol O, Hauser R et al (2014) Phase-3 clinical trial of the adenosine 2a antagonist preladenant, given as monotherapy, in patients with Parkinson's disease. Neurology 82:S7.004
198. Stone TW, Ceruti S, Abbracchio MP (2009) Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 193:535-587
199. Sutherland GR, Peeling J, Lesiuk HJ et al (1991) The effects of caffeine on ischemic neuronal injury as determined by magnetic resonance imaging and histopathology. Neuroscience 42:171-182
200. Takeuchi H (2013) Roles of glial cells in neuroinflammation and neurodegeneration. Clin Exp Neuroimmunol 4:2-16
201. Tan EK, Tan C, Fook-Chong SM et al (2003) Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 216:163-167
202. Toncev G (2006) Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. Vojnosanit Pregl 63:879-882
203. Vargas MR, Johnson DA, Sirkis DW et al (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 28:13574-13581
204. Vitart V, Rudan I, Hayward C et al (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40:437-442
205. Von Lubitz DK, Lin RC, Melman N et al (1994) Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol 256:161-167
206. Watanabe S, Kang DH, Feng L et al (2002) Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40:355-360
207. Weisskopf MG, O'Reilly E, Chen H et al (2007) Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166:561-567
208. Wills AM, Eberly S, Tennis M et al (2013) Caffeine consumption and risk of dyskinesia in CALMPD. Mov Disord 28:380-383
209. Winquist A, Steenland K, Shankar A (2010) Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov Disord 25:932-936
210. Wostyn P, Van Dam D, Audenaert K et al (2011) Increased cerebrospinal fluid production as a possible mechanism underlying caffeine's protective effect against Alzheimer's disease. Int J Alzheimers Dis 2011:617420
211. Wu XW, Muzny DM, Lee CC et al (1992) Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34:78-84
212. Xiao D, Bastia E, Xu YH et al (2006) Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine- induced dyskinesia in hemiparkinsonian mice. J Neurosci 26:13548-13555
213. Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310
214. Yadav V, Bever C Jr, Bowen J et al (2014) Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 82:1083-1092
215. Yamamoto N, Sawada H, Izumi Y et al (2007) Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 282:4364-4372
216. Yao SQ, Li ZZ, Huang QY et al (2012) Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis. J Neurochem 123:100-112
217. Yeum KJ, Russell RM, Krinsky NI et al (2004) Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 430:97-103
218. Yu ZF, Bruce-Keller AJ, Goodman Y et al (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 53:613-625
219. Yu L, Shen HY, Coelho JE et al (2008) Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338-346
220. Zeitlin R, Patel S, Burgess S et al (2011) Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res 1417:127-136
221. Zhang N, Shu HY, Huang T et al (2014) Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS One 9:e100286
222. Zheng Z, Guo X, Wei Q et al (2014) Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metab Brain Dis 29:771-775
223. Zhu TG, Wang XX, Luo WF et al (2012) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 506:175-179
224. Zoccolella S, Simone IL, Capozzo R et al (2011) An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol 258:238-243